Terms: = Colorectal cancer AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C
88 results:
1. High expression of shp2 predicts a promising prognosis in colorectal cancer.
Liu X; Li M; Chen L; Wen F; Zheng S; Ge W
Indian J Pathol Microbiol; 2024; 67(1):29-35. PubMed ID: 38358185
[TBL] [Abstract] [Full Text] [Related]
2. Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.
Shang Y; Fu S; Hao Q; Ying H; Wang J; Shen T
Bioorg Chem; 2024 Mar; 144():107092. PubMed ID: 38271825
[TBL] [Abstract] [Full Text] [Related]
3. Unveiling the role of KRAS in tumor immune microenvironment.
Xu M; Zhao X; Wen T; Qu X
Biomed Pharmacother; 2024 Feb; 171():116058. PubMed ID: 38171240
[TBL] [Abstract] [Full Text] [Related]
4. Combating KRASG12C Inhibitor Resistance.
Cancer Discov; 2024 Jan; 14(1):OF3. PubMed ID: 37921413
[TBL] [Abstract] [Full Text] [Related]
5. RNA-Seq Analysis Reveals Altered Expression of Cell Adhesion-Related Genes Following PZR Knockout in Lung cancer Cells.
Fu Y; Li G; Fu X; Xing S; Zhao ZJ
Appl Biochem Biotechnol; 2024 Apr; 196(4):2122-2136. PubMed ID: 37470934
[TBL] [Abstract] [Full Text] [Related]
6. Macrophage-derived shp-2 inhibits the metastasis of colorectal cancer via Tie2-PI3K signals.
Wu X; Guan S; Lu Y; Xue J; Yu X; Zhang QI; Wang X; Li T
Oncol Res; 2023; 31(2):125-139. PubMed ID: 37304233
[TBL] [Abstract] [Full Text] [Related]
7. shp2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.
Drilon A; Sharma MR; Johnson ML; Yap TA; Gadgeel S; Nepert D; Feng G; Reddy MB; Harney AS; Elsayed M; Cook AW; Wong CE; Hinklin RJ; Jiang Y; Brown EN; Neitzel NA; Laird ER; Wu WI; Singh A; Wei P; Ching KA; Gaudino JJ; Lee PA; Hartley DP; Rothenberg SM
Cancer Discov; 2023 Aug; 13(8):1789-1801. PubMed ID: 37269335
[TBL] [Abstract] [Full Text] [Related]
8. MUC1-C is necessary for shp2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.
Morimoto Y; Yamashita N; Hirose H; Fushimi A; Haratake N; Daimon T; Bhattacharya A; Ahmad R; Suzuki Y; Takahashi H; Kufe DW
Cancer Lett; 2023 Apr; 559():216116. PubMed ID: 36878307
[TBL] [Abstract] [Full Text] [Related]
9. Waking immune-resistant tumors with neddylation.
Huntoon K; Jiang W; Kim BY
J Clin Invest; 2023 Feb; 133(4):. PubMed ID: 36787255
[TBL] [Abstract] [Full Text] [Related]
10. Efficacious Combination Drug Treatment for colorectal cancer That Overcomes Resistance to KRAS G12C Inhibitors.
Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM
Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229
[TBL] [Abstract] [Full Text] [Related]
11. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
[TBL] [Abstract] [Full Text] [Related]
12. shp2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis.
Li Y; Zhou H; Liu P; Lv D; Shi Y; Tang B; Xu J; Zhong T; Xu W; Zhang J; Zhou J; Ying K; Zhao Y; Sun Y; Jiang Z; Cheng H; Zhang X; Ke Y
J Clin Invest; 2023 Feb; 133(4):. PubMed ID: 36626230
[TBL] [Abstract] [Full Text] [Related]
13. Preventing Surgery-Induced NK Cell Dysfunction Using Anti-TGF-β Immunotherapeutics.
Market M; Tennakoon G; Scaffidi M; Cook DP; Angka L; Ng J; Tanese de Souza C; Kennedy MA; Vanderhyden BC; Auer RC
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498937
[TBL] [Abstract] [Full Text] [Related]
14. Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 colorectal cancer Cells.
Wang M; Xiang Y; Wang R; Zhang L; Zhang H; Chen H; Luan X; Chen L
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431875
[TBL] [Abstract] [Full Text] [Related]
15. Targeted Next-Generation Sequencing-Based Multiple Gene Mutation Profiling of Patients with Rectal Adenocarcinoma Receiving or Not Receiving Neoadjuvant Chemoradiotherapy.
Chang YK; Tseng HH; Leung CM; Lu KC; Tsai KW
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142267
[TBL] [Abstract] [Full Text] [Related]
16. Targeting RAS Mutant colorectal cancer with Dual Inhibition of MEK and CDK4/6.
Sorokin AV; Kanikarla Marie P; Bitner L; Syed M; Woods M; Manyam G; Kwong LN; Johnson B; Morris VK; Jones P; Menter DG; Lee MS; Kopetz S
Cancer Res; 2022 Sep; 82(18):3335-3344. PubMed ID: 35913398
[TBL] [Abstract] [Full Text] [Related]
17. Clinical considerations for the design of PROTACs in cancer.
Nieto-Jiménez C; Morafraile EC; Alonso-Moreno C; Ocaña A
Mol Cancer; 2022 Mar; 21(1):67. PubMed ID: 35249548
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic significance of shp2 (ptpn11) expression in solid tumors: A meta-analysis.
Zhou J; Guo H; Zhang Y; Liu H; Dou Q
PLoS One; 2022; 17(1):e0262931. PubMed ID: 35061863
[TBL] [Abstract] [Full Text] [Related]
19. Predictive and Therapeutic Implications of a Novel PLCγ1/shp2-Driven Mechanism of Cetuximab Resistance in Metastatic colorectal cancer.
Cruz-Duarte R; Rebelo de Almeida C; Negrão M; Fernandes A; Borralho P; Sobral D; Gallego-Paez LM; Machado D; Gramaça J; Vílchez J; Xavier AT; Ferreira MG; Miranda AR; Mansinho H; Brito MJ; Pacheco TR; Abreu C; Lucia-Costa A; Mansinho A; Fior R; Costa L; Martins M
Clin Cancer Res; 2022 Mar; 28(6):1203-1216. PubMed ID: 34980600
[TBL] [Abstract] [Full Text] [Related]
20.
Coupez D; Hulo P; Touchefeu Y; Denis MG; Bennouna J
Expert Opin Biol Ther; 2021 Oct; 21(10):1325-1334. PubMed ID: 34378483
[TBL] [Abstract] [Full Text] [Related]
[Next]
